Steroid hormone receptors (SHRs) are ligand-activated transcription factors that regulate gene expression. SHRs also mediate rapid, nongenomic cellular activation by steroids. In vascular endothelial cells, the SHR for estrogen, estrogen receptor (ER) ␣, is targeted by unknown mechanisms to a functional signaling module in membrane caveolae that enables estrogen to rapidly activate the mitogen-activated protein kinase and phosphatidylinositol 3-Akt kinase pathways, and endothelial NO synthase (eNOS). Here we identify the 110-kDa caveolin-binding protein striatin as the molecular anchor that localizes ER␣ to the membrane and organizes the ER␣-eNOS membrane signaling complex. Striatin directly binds to amino acids 183-253 of ER␣, targets ER␣ to the cell membrane, and serves as a scaffold for the formation of an ER␣-G␣i complex. Disruption of complex formation between ER␣ and striatin blocks estrogen-induced rapid activation mitogenactivated protein kinase, Akt kinase, and eNOS, but has no effect on ER-dependent regulation of an estrogen response elementdriven reporter plasmid. These findings identify striatin as a molecular scaffold required for rapid, nongenomic estrogen-mediated activation of downstream signaling pathways. Furthermore, by demonstrating independent regulation of nongenomic vs. genomic ER-dependent signaling, these findings provide conceptual support for the potential development of ''pathway-specific'' selective ER modulators.
strogen, acting via its two receptors, ER␣ and ER␤, exerts diverse effects on a variety of tissues (reviewed in ref. 1) . Estrogen receptors (ERs) regulate cellular function via two signaling pathways referred to as ''genomic'' and ''nongenomic.'' Genomic effects of estrogen are mediated by nuclear ERs that act as ligand-activated transcription factors. Nongenomic effects of estrogen are also mediated by ERs, but they occur relatively rapidly and do not involve alterations in gene expression. We and others (2) (3) (4) (5) (6) (7) (8) (9) have shown that vascular cells express ERs capable of mediating both genomic and nongenomic effects. Nongenomic effects of estrogen in the vasculature have been best studied in vascular endothelial cells. In these cells, estrogen rapidly and sequentially activates the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase-Akt kinase pathways, which increases the activity of endothelial NO synthase (eNOS) (4, (10) (11) (12) (13) . This pathway contributes to the rapid, estrogen-induced arterial vasodilation observed in clinical studies (14, 15) . ER␣ is required for rapid activation of eNOS by estrogen (4, (10) (11) (12) , and recent reports demonstrate that these nongenomic effects are transduced by a subpopulation of ER␣ localized to caveolae (3), cell membrane microdomains important for many signaling pathways. However, the molecular mechanisms by which ER␣ localizes to the caveolae and the details by which ER␣ activates membrane-associated eNOS remain obscure.
We now report the identification of striatin as an ER␣-binding protein. Striatin is a 780-aa protein first isolated from rat brain synaptosomes (16, 17) . Striatin is a calmodulin-binding member of the WD-repeat family of proteins and contains at least four protein-protein interaction domains, including caveolin-binding (amino acids 55-63), coiled-coil (amino acids 70-116), Ca 2ϩ -calmodulin-binding (amino acids 149-166), and a series of eight WD repeat (amino acids 419-780) motifs (16) (Fig. 1 A) . WD repeats are found in a wide variety of proteins, including the signal-transducing G protein ␤-subunit, as well as other proteins that organize and regulate signal transduction, cytoskeletal organization, and vesicular fusion (18) . Striatin also forms a complex with protein phosphatase 2A (19) , which we have shown recently also binds directly to and regulates the function of ER␣ (20) . We now show further that striatin targets ER␣ to the cell membrane and serves as a scaffold for the assembly of proteins required for rapid, estrogen-induced activation of eNOS. For the protein expression studies, cells were transfected by electroporation as described (6, 21) . For luciferase assays, cells were transfected with PolyFect (Qiagen, Valencia, CA). Cos1 cells were plated in 12-well plates and cultured in DMEM without phenol red with 10% estrogen-deficient FBS overnight. After transfection (20 h), the cells were washed and treated with either 10 Ϫ8 M E2 or vehicle for 9 h. Cells were lysed in reporter lysis buffer (Promega), and luciferase assays (luciferase assay system, Promega) and ␤-galactosidase assays (Tropix, Bedford, MA) were performed according to the manufacturer's guidelines.
Methods
Plasmids. The bait plasmid PGBT9-ER␣ was constructed by inserting the 1.8-kb full-length cDNA of human ER␣ into the EcoRI site of the Gal4 DNA-binding domain vector pGBT9 (Clontech). The pGAD10-ER␣ and pGAD10-ER␤ plasmids were cloned by insert- Abbreviations: ER, estrogen receptor; MAPK, mitogen-activated protein kinase; eNOS, endothelial NO synthase; E2, 17␤-estradiol; IGFR, insulin-like growth factor receptor; EGFR, epidermal growth factor receptor; PTX, pertussis toxin. ‡ Under agreements between Upstate Biotechnology and Emory University, D.C.P. is entitled to a share of sales royalty received by the University from these companies. In addition, he serves as a consultant to Upstate Biotechnology. The terms of this arrangement have been reviewed and approved by Emory University in accordance with its conflict of interest policies. § To whom correspondence should be addressed. E-mail: rkaras@tufts-nemc.org.
© 2004 by The National Academy of Sciences of the USA ing full-length ER␣ and ER␤ into pGAD10 vector (Clontech). The expression plasmids pCMV3-ER␣, pCMV3 ER-271, and the reporter plasmid ERE-Luc have been described (20, 21) . pCMV3-striatin was constructed by cloning full-length rat striatin cDNA into pCDNA 3.1 (Invitrogen). The pEGFP-H1 and pEGFP-ER176-253 constructs were made by cloning N-terminal striatin 1-203 and PCR-derived ER␣ 176-253 into pEGFP-C2 vector (Clontech) into the EcoRI site and EcoRI͞SmaI sites, respectively. The G␣i2 expression plasmid was obtained from the Guthrie Research Institute (Sayre, PA). The plasmids for the GST pull-down experiments were constructed by cloning the full-length G␣i2, H1 (striatin ), full-length ER␣, truncated mutants ER␣ 1-271 and ER␣ 176-595, and PCR-derived ER␣ fragments including ER␣ 176-253, 254-370, 176-282, and 183-253 into pGEX-4T-1 (Amersham Pharmacia). GST-striatin was a kind gift from A. Monneron (Université de la Méditerranée, Marseille, France). The pTAT-HA vector with 6-His-tag was a kind gift from S. F. Dowdy (Washington University School of Medicine, St. Louis). A PCR-generated KpnI-EcoRI fragment containing ER␣ 176-253 was cloned into the corresponding sites of plasmid pTAT-HA vector.
Yeast Two-Hybrid Screen. The yeast two-hybrid screen was performed by using a human heart cDNA library (Clontech). The human full-length ER␣ was cloned as ''bait'' into the Gal4 DNA-binding domain vector pGBT9. PGBT9 ER␣ and the human heart library were transformed into yeast strain Y190 (lacZ and HIS3 reporter genes) by using the lithium acetate method. The transformants were selected for growth on synthetic dropout selective medium plus 3-amino 1,2,4-triazole. Clones were screened for the ability to transactivate both histidine and ␤-galactosidase reporters. The interaction between ER␣ and H1 was confirmed by reintroduction of the individual plasmids into the host yeast Y190.
GST Pull-Down and in Vitro Binding Assay. GST fusion pulldown experiments were performed as described (20) . Recombinant human ER␣ (50 ng; Calbiochem) was used instead of cell lysates in a subset of these experiments.
Immunoprecipitation. Immunoprecipitation and coimmunoprecipitation experiments were performed as described (20) .
In Vitro Binding Assay. GST or GST fusion proteins were incubated with rER␣ in the presence or absence of partially purified full-length striatin or N-terminal striatin (H1). Partially purified striatin was prepared as follows. Striatin was immunoprecipitated from Cos1 cell lysates as described above, and the immunopellet was resuspended in 0.2 ml of resolubilization buffer (50 mM Tris, pH 7.5͞5 mM DTT͞0.5% SDS). This solution was boiled for 5 min, and after addition of 1 ml of Tris lysis buffer (TLB) it was centrifuged for 5 min at 14,000 ϫ g. A second immunoprecipitation was carried out on the supernatant, and these immunopellets were resolubilized in 0.2 ml of resolubilization buffer, diluted with 1 ml of TLB, and used for in vitro binding assays. The remainder of the GST pulldown protocol described above was then carried out.
Cell Fractionation. EAhy926 cells were cotransfected with ER␣ and striatin plasmids or ER␣ and control vector by electroporation. The cells were plated in 100-mm dishes and grown in phenol red-free DMEM in 10% estrogen-deficient FBS for 24 h after transfection. Lysates were prepared in 1 ml of homogeni- zation buffer (20 mM Tris⅐HCl, pH 7.5͞100 mM NaCl͞1 mM EDTA͞1 mM PMSF͞protease inhibitor mixture). Crude lysates were centrifuged at 3,000 ϫ g for 10 min at 4°C. The pellet containing nuclear proteins was recovered. The postnuclear supernatant fraction was next centrifuged at 45,000 ϫ g for 1 h at 4°C, and the cell membrane pellet was recovered. The fractionated pellets were resuspended in Tris lysis buffer. The purity of isolation of the plasma membrane and nuclear fractions was examined by immunoblotting for membrane proteins [epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor (IGFR)] and the nuclear protein histone.
Immunoblotting. Protein samples were resolved by SDS͞PAGE, transferred to nitrocellulose membranes, and immunoblotted with the appropriate primary Ab. Abs used include anti-ER␣ (Ab7; 1:200, NeoMarker), anti-striatin (1:1,000, Transduction Laboratories), anti-EGFR, anti-IGFR, and anti-histone (1:500; Santa Cruz Biotechnology), anti-G␣i (1:1000, Calbiochem), anti-eNOS, phospho-eNOS, MAPK, phospho-MAPK (1:1,000, Cell Signaling Technology), and AKT and phospho-AKT (1:1,000, Pharmingen). The immunoblots were then visualized by ECL (Amersham Pharmacia).
Immunostaining. EAhy926 cells cotransfected with ER␣ and striatin plasmids or ER␣ and control vector, were plated in 12-well tissue culture plates (Becton Dickinson Labware) on coverslips and grown in phenol red-free DMEM in 10% estrogen-deficient FBS for 24 h. The cells were fixed in 3.7% paraformaldehyde for 10 min and permeabilized with 0.3% Triton X-100 for 15 min. After blocking with 10% donkey serum for 1 h, double immunostaining was performed by incubating the cells with rabbit anti-ER␣ HC 20 (1:500, from Santa Cruz Biotechnology) and mouse anti-striatin Ab (1:1,000) for 1 h, washing three times with PBS followed by incubation with FITC-conjugated donkey anti-rabbit secondary Ab (1:200) and Cy3-labeled donkey anti-mouse secondary Ab (1:1,000) (secondary Abs were purchased from Jackson ImmunoResearch) and then examined by fluorescence microscopy.
Purification of Permeable Tat-ER␣ Fragment Fusion Peptides. The pTat-HA ER␣ 176 -253 plasmid was then transformed into Escherichia coli XL10-gold strain. Protein expression was induced by using 0.2 mM isopropyl ␤-D-thiogalactoside for 5 h at 37°C. Bacterial pellets were resuspended in 10 ml of buffer Z (8 M urea͞100 mM NaCl͞20 mM Hepes, pH 8.0), sonicated, and centrifuged at 12,000 ϫ g for 20 min, and the supernatant was equilibrated in 10 mM imidazole. The fusion proteins were purified by using Ni-NTA agarose (Invitrogen). The Tat fusion peptides were then eluted in 5 ml of buffer Z containing 100, 250, and 500 mM imidazole, followed by desalting on a PD-10 column (Amersham Biosciences).
Statistical Analysis. Unless indicated otherwise, all experimental results presented represent a minimum of three independent experiments. In Fig. 4 , mean values were compared by using Student's t test, and P Յ 0.05 was considered significant.
Results
A yeast two-hybrid system screen by using full-length human ER␣ as bait led to isolation of clone H1 (data not shown), which proved identical to the first 203 aa of striatin.
Immunoprecipitation studies demonstrated that striatin complexes with ER␣ in mammalian cells. Striatin and ER␣ were consistently coimmunoprecipitated from a variety of cell types, including EAhy926 endothelial cells, which contain the functional ER␣-eNOS membrane signaling complex (22) (Fig.  1B) . Notably, in some experiments, striatin appears as a doublet which might be due to different phospho-forms of the protein. The ER␣-striatin interaction was enhanced substantially by short-term exposure of cells to E2 (Fig. 1C) . In vitro studies with GST-striatin fusion proteins also demonstrated complex formation between striatin and ER␣ in cell lysates and direct binding of striatin to recombinant ER␣ (Fig. 1D) . Studies with ER␣ deletion mutants identified the region of ER␣ that mediates striatin binding as amino acids 183-253 in the N-terminal A͞B domain of ER␣ (Fig. 1E) , and this was confirmed by reciprocal experiments by using a GST-striatin fusion peptide (amino acids 1-203) with lysates of cells expressing either full-length ER␣ or ER␣ deletion mutants (data not shown).
In EAhy926 cells, ER␣ is localized primarily in the nucleus with only a small proportion in the region of the plasma membrane ( Fig. 2A) , whereas striatin is detectable only weakly (Fig. 2B) . Overexpression of striatin markedly changes the distribution of ER␣ by substantially increasing the proportion of ER␣ that is distributed along the plasma membrane (Fig. 2D) . Membrane-associated ER␣ appears in a highly concentrated, punctate pattern, as does a subpopulation of striatin (Fig. 2E) that colocalizes with the plasma membrane ER␣ (Fig. 2F) . In unstimulated cells, striatin also colocalizes along the plasma membrane with eNOS ( Fig. 2 G-I) . Membrane-associated ER␣ has previously been shown to activate growth factor receptor tyrosine kinases such as IGFR (23) and EGFR (24) , which reside in caveolae (25) . Overexpression of striatin substantially increases the amount of ER␣ in the membrane-enriched fraction containing EGFR (Fig. 2 J) and IGFR (data not shown) and slightly decreases the amount of ER␣ in the nuclear fraction ( Fig. 2 J) , although it has no effect on the overall abundance of ER␣ in the cell (data not shown).
Previous reports have shown that E2-induced activation of both the MAPK and Akt kinase cascades (4) is preceded by formation of a complex between ER␣ and G␣i in endothelial cells and in Cos cells transfected with eNOS and ER␣ (11, 12, 26) . E2 activation of eNOS was reported to be blocked by PTX (26) and the ER antagonist ICI 182,780, supporting that eNOS stimulation by E2 requires activation of both ER␣ and G␣i (26) (27) (28) . As shown in Fig. 3A , in endothelial cells, E2 stimulates formation of a complex containing ER␣, G␣i, and striatin, and formation of this complex is inhibited by either PTX or ICI 182,780. PTX also abolishes E2-induced phosphorylation of MAPK (Fig. 3B) and Akt kinase (data not shown). We tested whether G␣i binds directly to ER␣ or striatin by using recombinant proteins. Although an interaction was observed between striatin and ER␣, no interaction was detectable between G␣i and ER␣ under identical experimental conditions (Fig. 3C) . In contrast, full-length, but not N-terminal striatin, bound G␣i (Fig.  3D) , suggesting that striatin mediates, and is necessary for complex formation between G␣i and ER␣. To more directly test this possibility, recombinant ER␣ was incubated with G␣i in the absence or presence of full-length striatin or an N-terminal striatin peptide. Minimal complex formation was observed between G␣i and ER␣ in the absence of striatin (Fig. 3E) . In the presence of full-length striatin, more abundant G␣i-ER␣ complex formed. This complex was not observed in the presence of a truncated, N-terminal striatin peptide (Fig. 3E) . These data support that striatin mediates the formation of a complex between ER␣ and G␣i, and that the G protein binds to a domain(s) of striatin outside of the N-terminal 203 aa containing the ER␣-binding site (compare Fig. 1D ). These data are consistent with a model in which the C-terminal WD domain(s) of striatin mediate G␣i binding, similar to the role of the WD domains in the interaction between subunits of the heterotrimeric G proteins (29) . GST fusion pulldown experiments and coimmunoprecipitation approaches both showed that striatin also forms a complex that contains eNOS (Fig. 3F) .
To test whether striatin is required for activation of the ER␣-phosphatidylinositol 3-kinase-Akt-eNOS signaling pathway, blocking peptides were first developed and tested for their ability to disrupt the ER␣-striatin interaction. Mammalian expression vectors and Tat fusion proteins (30) were created that express amino acids 176-253 of ER␣, the region that mediates its interaction with striatin, an approach that we have used previously to disrupt protein-protein interactions required for signal transduction (20, 31, 32) . The amino acids 176-253 blocking peptide disrupts binding between ER␣ and striatin both in overexpression studies (Fig. 4A) and when introduced into cells as a Tat fusion peptide (30) (data not shown). Disruption of the ER␣-striatin interaction moderately enhances E2-mediated transcriptional activation of an estrogen response element-driven reporter plasmid by the ER (Fig. 4B) , supporting that disruption of the ER␣-striatin interaction does not abolish transcriptional activation of the ER. These data do not, however, rule out the possibility that striatin binding of ER␣ participates in the regulation of ER␣-mediated transcription of endogenous genes. E2, via ER␣, also rapidly activates MAPK in endothelial cells and in COS cells transfected with ER␣ and eNOS (4, 33) . Overexpression of the ER␣-striatin blocking peptide prevented E2-induced MAPK activation (Fig. 4C) . In all cases, similar results were obtained when blocking peptide was delivered to cells by using the Tat fusion peptide approach (data not shown). Endothelial cells expressing endogenous ER␣ and eNOS were studied to test the importance of the ER␣-striatin interaction in the rapid activation of eNOS by E2 in intact cells. E2 activated Akt and eNOS, as assessed by an increased level of phosphorylation of each protein, and this was completely abolished when the ER␣-striatin interaction was disrupted by the blocking peptide (Fig. 4 D and E) . These data show that the interaction between ER␣ and striatin is required for E2 to activate Akt and eNOS in endothelial cells and that disruption of the ER␣- G␣i binds to the C terminus of striatin. GST fusion proteins containing either full-length striatin or the N terminus of striatin (striatin were incubated with lysates of Cos1 cells transfected with G␣i. (E) Striatin is required for complex formation between ER␣ and G␣i. GST or GST-G␣i fusion proteins were incubated with recombinant (rER), in the absence or presence of purified full-length striatin or striatin 1-203. rER␣, recombinant ER␣. (F) Striatin forms a complex with eNOS. eNOS was identified by immunoblotting in GST fusion pulldowns and by coimmunoprecipitation of lysates from EAhy926 cells. striatin interaction does not abolish ligand-activated transcription by ER␣.
Discussion
These studies identify striatin as a scaffold that promotes localization of ER␣ to the plasma membrane and assembly of the signaling complex of ER␣ and G␣i that is required for ER␣-dependent activation of MAPK, phosphatidylinositol 3-Akt kinase, and eNOS, a critical regulator of many physiologic and pathophysiologic processes. Estrogen regulates fundamental physiological processes in both reproductive and nonreproductive target tissues, including bone, brain, and the cardiovascular system. The diversity of estrogen action results in part from the ability of ERs to act as both transcription factors that regulate gene expression (i.e., genomic effects) and as signaling proteins that rapidly recruit and activate kinase-dependent signaling pathways (nongenomic effects). The genomic effects of estrogen are themselves quite diverse, in part as a result tissue-specific differences in expression levels of the ERs and ER-interacting proteins (e.g., coactivators and corepressors). The existence of these tissue-specific differences in estrogen action has given rise to the concept of ''tissue-specific'' selective ER modulators. Selective ER modulators are pharmacologic agents that act as ER agonists in some tissues but ER antagonists in others.
Although nongenomic effects of estrogen were first described almost three decades ago (34) , and related effects have been described for all major steroid hormones (35) , the molecular mechanisms that mediate rapid effects of steroid hormones are not yet well understood. Identification of striatin as a molecule specific to and required for nongenomic activation of eNOS by estrogen provides a new opportunity to dissect nongenomic steroid hormone receptor signaling pathways from ER-signaling pathways that regulate transcription. These data also potentially provide an opportunity to design pathway-specific selective ER modulators capable of differentially regulating nongenomic vs. genomic effects that may prove useful ultimately as specific therapies in breast cancer, osteoporosis, and cardiovascular disease. Overexpression of the blocking peptide ER 176 -271 prevents E2-induced phosphorylation of Akt kinase. EAhy926 cells expressing endogenous ER␣ were incubated with Tat-GFP (E) or Tat-ER176-253 (■) for 6 h before E2 treatment. Total protein lysates were then immunoblotted for phospho-AKT (pAKT) normalized for the amount of total Akt. These ratios were normalized to one for the vehicle-treated cells. Results represent mean Ϯ SE derived from four independent experiments. * , P Ͻ 0.05 vs. time 0. (E) Overexpression of the blocking peptide ER176-253 prevents E2-induced phosphorylation of eNOS.
EAhy926 were incubated with Tat-GFP (E) or Tat-ER176-253 (■) for 6 h before E2 treatment. Total protein lysates were then immunoblotted for phospho-eNOS (peNOS) normalized for the amount of total eNOS. These ratios were normalized to one for the vehicle-treated cells. Results represent mean Ϯ SE derived from four independent experiments. * , P Ͻ 0.05 vs. time 0.
